Suicide Risk With SSRIs Cannot Be Ruled Out

	Tweet

The findings from two reviews of trial data suggest that it would be premature to conclude that selective serotonin reuptake inhibitor (SSRI) use does not have some effect on suicide risk. Moreover, results from a case-control study support a weak link between SSRI use and self harm among pediatric users.

All three reports appear in the February 19th issue of the British Medical Journal.

In the first study, Dr. Dean Fergusson, from the Ottawa Health Research Institute in Canada, and colleagues analyzed data from more than 87,000 patients enrolled in 702 trials that compared the effects of an SSRI with that of placebo or an active non-SSRI control.

SSRI-treated patients were 2.28-times more likely to attempt suicide than were placebo users. Similarly, SSRI use nearly doubled the risk of suicide attempts compared with use of non-tricyclic antidepressant agents.

Dr. David Gunnell, from the University of Bristol in the UK, and colleagues conducted a meta-analysis involving over 40,000 patients enrolled in 477 randomized, controlled trials. Although the authors found no evidence that SSRI use raised the risk of suicide, they note that “important protective or hazardous effects cannot be excluded.” However, there was weak evidence that these drugs increased the risk of self-harm.

Lastly, Dr. Carlos Martinez, from the Medicines and Healthcare products Regulatory Agency in London, and colleagues conducted a case-control study of 146,095 depressed individuals to assess the suicide risk seen with SSRI use compared with tricyclic antidepressant use.

Among adults, there was no evidence that SSRI use raised the risk of suicide or non-fatal self-harm to a greater extent than tricyclic antidepressants. In children and adolescents, by contrast, SSRI use increased the risk of non-fatal self-harm by 59%. No suicides were observed in this younger age group.

In a related editorial, Dr. Andrea Cipriani, from the University of Verona in Italy, and colleagues comment that in adults, clinicians “need to balance the benefits and harms” of prescribing SSRIs. By contrast, in children and adolescents, the risks generally outweigh the benefits and such drugs should not be prescribed on a routine basis.

BMJ 2005;330:373-374,385-393,396-399.

RELATED STORIES:
Study says partner’s suicide raises person’s own risk   Premature babies pre-disposed to psychiatric problems in teens   Working Overtime Linked to Anxiety and Depression   Smoking tied to suicide risk in bipolar disorder   Mental health disorders common in young adults   Human and economic burden of generalized anxiety disorder   Post-traumatic stress disorder, resilience and vulnerability   B vitamins linked to depression risk in older adults   Depression frequent and highly persistent in 85-plus   Mental health treatment extends lives of older patients with diabetes and depression   Can Mental Activity Protect Against Memory Problems in MS?   Study identifies 3 effective treatments for childhood anxiety disorders   Self-guided Depression Treatment   Routine Tylenol for Dementia Patients Increases Activity   Researchers Find Depressed Teens Respond Well to Combination Therapy

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]